BriaCell Therapeutics’ stock surged on Wednesday after the company announced encouraging overall survival data from its Phase 2 clinical trial of Bria-IMT in combination with an immune checkpoint inhibitor (CPI) for late-stage metastatic breast cancer. The data revealed a significant improvement in survival compared to previously reported findings and similar patients treated with other methods.